Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 4500 participants.

Also called NCT06396858

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 4,500 participants (planned count) (from the registry)
Sponsor
Brazilian Clinical Research Institute (from the registry)
Registry
  • NCT NCT06396858
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06396858. Randomized; quadruple masking; primary purpose prevention. Start 2027-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
Acronym
ARCHIMEDES
Intervention (Drug)
Rivaroxaban 2.5 Mg Oral Tablet
Intervention (Drug)
Colchicine 0.5 MG
Intervention (Drug)
Placebo Rivaroxaban
Intervention (Drug)
Placebo Colchicine
Lead sponsor
Brazilian Clinical Research Institute (class: other)
Collaborator
Alliança Diagnostic (class: not stated)

Record details

Record id
cardio:ct-nct06396858
Content hash
0bc018769f195ac3842ff306d532f01f6bb786293e10fc157396a7b9ed4a02bb